Reuters logo
BRIEF-Ultragenyx reports third quarter 2017 financial results
November 2, 2017 / 8:27 PM / 18 days ago

BRIEF-Ultragenyx reports third quarter 2017 financial results

Nov 2 (Reuters) - Ultragenyx Pharmaceutical Inc

* Ultragenyx Pharmaceutical Inc- ‍cash, cash equivalents, and investments were $396.0 million as of September 30, 2017​

* Q3 loss per share $1.87

* Q3 earnings per share view $-1.86 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below